Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

devimistat 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × C04.588.274.476.411.307 × Bevacizumab × Clear all
NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Cornerstone Pharmaceuticals

Phase 1 Withdrawn

C04.588.274.476.411.307

Data powered by HemOnc (CC BY 4.0) Colophon âš¡